6-K ·Filed Apr 22, 2026

EVAX

Evaxion A/S
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001171843-26-002632
Notable filing: 6-K
Actionable Insight • Neutral

Monitor future warrant issuances and potential convertible note offerings as these could lead to dilution or new debt. The changes are administrative and do not signal immediate financial moves.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
EVAX ▼ -27.99% at T+60d
NEUTRAL call ✗ call lost -27.99% · α vs SPY -32.77% · entry $4.27 → $3.08
Entry anchored
Apr 21, 03:04 PM ET
via exchange tick
T+1d
-0.47%
call -0.47% · α -0.07%
$4.25
settled 5mo ago
T+5d
0.00%
call 0.00% · α -0.05%
$4.27
settled 5mo ago
T+20d
-6.79%
call -6.79% · α -9.96%
$3.98
settled 5mo ago
T+60d
-27.99%
call -27.99% · α -32.77%
$3.08
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Evaxion A/S held its Annual General Meeting on April 16, 2026, where shareholders approved amendments to the company's Articles of Association. The key changes include increasing the board's authorization to issue warrants for employee incentives to DKK 11.9 million and replacing a lapsed authorization with a new one to obtain loans via convertible notes worth up to DKK 73.5 million. The company's Articles of Association were updated to reflect these changes.

Key Facts

  • Annual General Meeting held on April 16, 2026.
  • Shareholders approved amendments to the Articles of Association.
  • Authorization to issue warrants for employee incentives increased to DKK 11.9 million.
  • New authorization to obtain loans via convertible notes up to DKK 73.5 million approved.
  • Articles of Association updated as of April 16, 2026.

Financial Impact

The amendments allow for potential future capital raises and employee incentives, but no immediate financial impact is reported.

dilutiondebt

Risk Factors

  • Future warrant exercises could dilute existing shareholders.
  • Convertible note offerings could increase the company's debt burden.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-002632
Document: f6k_042126.htm0001171843-26-002632
Document: 0001171843-26-002632-index-headers.html0001171843-26-002632
Document: 0001171843-26-002632-index.html0001171843-26-002632
Document: 0001171843-26-002632.txt0001171843-26-002632
36 reports for EVAX
Performance horizon
100% Hit rate 9 of 9 directional calls best @ T+5▲ +22.94%Mar 5, 2026
Filters
Rows
Reports for EVAX — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$3.07 $3.21▲ +4.56%▲ +4.45%$3.21 (+4.63%)
Sep 4, 2026
28d ago
6-K
BEARISH ★ 5/10
$3.12 $3.07▲ +1.60%▲ +0.39%$3.21 (−2.96%)
Aug 20, 2026
6w ago
6-K
NEUTRAL ★ 4/10
$3.28 $3.15▼ −3.96%▼ −5.08%$3.21 (−2.07%)
Aug 20, 2026
6w ago
Press Release
NEUTRAL ★ 4/10
$3.28 $3.15▼ −3.96%▼ −5.08%$3.21 (−2.07%)
Aug 17, 2026
6w ago
6-K
NEUTRAL ★ 4/10
$3.13 $3.40▲ +8.63%▲ +9.82%$3.21 (+2.63%)
Aug 14, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$3.34 $3.31▼ −0.90%▲ +0.47%$3.21 (−3.83%)
Aug 14, 2026
7w ago
Press Release
NEUTRAL ★ 2/10
$3.34 $3.31▼ −0.90%▲ +0.47%$3.21 (−3.83%)
Jul 17, 2026
11w ago
6-K
BULLISH ★ 7/10
$3.08 $3.05▼ −0.81%▼ −0.13%$3.21 (+4.46%)
Jul 17, 2026
11w ago
Press Release
NEUTRAL ★ 4/10
$3.08 $3.05▼ −0.81%▼ −0.13%$3.21 (+4.46%)
Jul 13, 2026
11w ago
6-K
NEUTRAL ★ 3/10
$3.02 $3.08▲ +1.82%▲ +2.61%$3.21 (+6.36%)
Showing 10 of 36

US Market Status

Market Open — Closes in 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access